Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic <i>via</i> hierarchical binding events at the plasma membrane

Yang Su(China Three Gorges Corporation (China)), Dirk Spitzer(Washington University in St. Louis)
Oncotarget
April 22, 2016
Cited by 16


Related Papers